Standard BioTools (LAB) Adopts New Equity Incentive Plan

This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.

The short version

Standard BioTools Inc. (LAB) filed its 2026 Equity Incentive Plan on June 18, 2026. The plan allows the company to grant up to roughly 24.8 million shares in stock options, restricted stock, and performance-based awards to employees and directors, with additional shares available from forfeitures of prior plan grants. The plan is subject to shareholder approval at the company's 2026 Annual Meeting of Stockholders.

Standard BioTools Inc. has adopted a new equity incentive plan, effective June 17, 2026, according to a filing made with the SEC on June 18, 2026.

Plan Size and Share Pool

The plan authorizes up to 24.8 million shares of company stock that can be granted to employees, executives, and outside directors. The company can also use shares that are forfeited, expire, or are cancelled from its prior 2011 Equity Incentive Plan, up to a ceiling of roughly 34.5 million total shares combined under the new arrangement.

Types of Awards

The plan allows the company to grant various forms of equity compensation, including stock options, restricted stock, restricted stock units (which are shares that vest over time), and performance-based awards (compensation earned only if specific company goals are met). The specific terms—like vesting schedules and performance targets—are set by the company's Board or administrator at the time of grant.

Key Limits and Restrictions

Outside directors (members of the Board who are not company employees) can receive a maximum of $750,000 in total awards and cash compensation in any single year, or $1 million in their first year of service.

No dividends or dividend equivalents will be paid on awards that have not yet vested. Awards cannot be transferred or sold by participants during their lifetime—they can only pass to heirs through a will or by inheritance laws.

Stock options must have an exercise price of at least 100 percent of the company's stock price on the day the option is granted. For executives who already own more than 10 percent of the company's voting power, the price must be at least 110 percent of the stock price on the grant date.

Change of Control Provisions

If the company is acquired or undergoes a change of control, and the buyer does not assume or replace the stock awards under substantially equivalent terms, then all awards will automatically vest in full and performance goals will be deemed met at 100 percent of target. This protects participants from losing equity value in a transaction.

Plan Duration and Shareholder Vote

The plan will terminate on April 24, 2036, unless the Board terminates it earlier. The plan is contingent on approval by Standard BioTools shareholders at the company's 2026 Annual Meeting of Stockholders.

Key facts

Standard BioTools Inc. (LAB) adopted a new 2026 Equity Incentive Plan, effective June 17, 2026

Plan authorizes up to 24,835,928 shares for grants to employees, executives, and outside directors

Combined with forfeitures from the prior 2011 plan, up to roughly 34.5 million shares may be available

Outside directors limited to $750,000 in annual awards and compensation (or $1 million in their first year)

Stock option exercise prices must be at least 100% of fair market value on grant date (110% for officers owning over 10% of company)

Awards automatically fully vest upon a change of control if not assumed by successor

Plan terminates April 24, 2036, unless terminated earlier by the Board

Plan is subject to shareholder approval at the 2026 Annual Meeting of Stockholders

Why it matters

Equity incentive plans are a routine governance matter for public companies, used to attract and retain talent by allowing employees and directors to own a stake in the company's future performance. This filing shows Standard BioTools is refreshing its equity compensation program after a gap since its prior 2011 plan, with a meaningful share pool of nearly 25 million shares. The automatic vesting upon change of control is a standard investor protection. However, this type of filing is administrative in nature and does not signal any material business change, transaction, or strategic shift—it simply establishes the framework for compensation decisions going forward, pending a shareholder vote.

Frequently asked

How many shares can Standard BioTools grant under this new plan?

The plan authorizes up to 24.8 million shares. The company can also use additional shares that are forfeited from its prior 2011 Equity Incentive Plan, up to a combined total of roughly 34.5 million shares.

What types of awards can the company grant?

The company can grant stock options (the right to buy shares at a set price), restricted stock (shares that vest over time), restricted stock units (cash or share awards that vest conditionally), and performance-based awards (compensation earned only if company goals are met).

What happens to employee equity if the company is acquired?

If the company is acquired and the buyer does not assume or replace the equity awards on substantially equivalent terms, all awards will automatically vest in full and any performance targets will be deemed achieved at 100 percent of the target level.

Does this plan need shareholder approval?

Yes, the plan is subject to approval by Standard BioTools shareholders at the company's 2026 Annual Meeting of Stockholders.

What the filing reported

5.02 Departure/Election of Directors or Officers

5.07 Other reported item

9.01 Financial Statements & Exhibits